X
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: New Part D study highlights benefit of switching plans

By Allyson Funk  |    September 26, 2016
With open enrollment beginning on October 15, it’s important for consumers to have adequate information to make the right decision about their health coverage and whether or not they should stay...   Read More

340B Spotlight: Trends in shifting site of care

By Rachel Licata  |    September 21, 2016
Research has shown once health care services shift from a provider’s office to a hospital, treatment costs for payers and patients increase. One way hospitals drive this site of care shift is...   Read More

New Survey: Patients’ share of health care costs continues to grow

By Allyson Funk  |    September 20, 2016
As we’ve highlighted before, a growing body of research continues to raise red flags about the implications of high cost sharing and patients’ ability to access affordable care – even if they have...   Read More

Patient voices missing from media conversation about prescription drug abuse

By Caitlin Carroll  |    September 19, 2016
Confronting and curtailing opioid abuse in America is a top public health priority and one to which PhRMA remains deeply committed. Mandating prescriber training, using state-based databases to...   Read More

Who gets a seat at ICER’s table? Hint: It’s not patients

By Holly Campbell  |    September 19, 2016
As we continue the move toward a value-driven health care system, efforts to develop tools supporting patient decision-making will play a central role. These tools, including emerging value...   Read More

Medicare Monday: New study highlights impact of variability in Medication Therapy Management programs

By Carolyn Ha  |    September 19, 2016
It’s almost the time of year for seniors to review their medications and select a Part D plan that best meets their needs. Included in Medicare Part D is the opportunity for qualifying...   Read More

2016 BCI Survey: A pro-innovation environment is essential for biopharmaceutical investment

By Guest Contributor  |    September 16, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

By Michelle Drozd  |    September 14, 2016
As part of PhRMA’s efforts to explore policy solutions to promote value-driven health care, we recently participated in a forum convened by Deloitte and the Network for Excellence in Health...   Read More

Medicare Monday: New research reveals Part D coverage is more robust than VA coverage for new, innovative medicines

By Allyson Funk  |    September 12, 2016
For 10 years, Medicare Part D has successfully provided access to affordable prescription drug coverage to seniors and people living with disabilities thanks to robust competition and negotiation...   Read More

New PhRMA report: New medicines in development for autoimmune diseases offer patients hope for brighter futures

By Hannah Mooney  |    September 12, 2016
Currently, more than 23.5 million Americans are affected by one of the more than 80 autoimmune diseases identified to date. These diseases range in severity, with their own characteristics and...   Read More

View Posts by Topic

see all

Subscribe to Email Updates